Acasti Pharma Inc EV / EBITDA

Was ist das EV / EBITDA von Acasti Pharma Inc?

EV / EBITDA von Acasti Pharma Inc ist N/A

Was ist die Definition von EV / EBITDA?



EV / EBITDA ist der Unternehmenswert geteilt durch das Einkommen vor Zinsen, Steuern, Abschreibungen und Amortisationen. Es ist ein Maß dafür, wie teuer eine Aktie ist und für Vergleiche zwischen Unternehmen häufiger gültig ist als das Preis-Gewinn-Verhältnis. Er misst den Preis (in Form des Unternehmenswerts), den ein Investor zu Gunsten des Cashflows des Unternehmens (in Form des EBITDA) bezahlt.

Price to earnings ratios are impacted by a company's choice of capital structure - companies which raise money via debt will have lower P/Es (and therefore look cheaper) than companies that raise an equivalent amount of money by issuing shares, even though the two companies might have equivalent enterprise values. A sample case is when a company with debt were to raise money by issuing shares of stock, and then used the money to pay off the debt, this company's P/E ratio would shoot up because of the increased number of shares - although nothing about the fundamental value of the business has changed. EV / EBITDA is unaffected by capital structure as enterprise value includes the value of debt, and EBITDA is available to all investors (debt and equity) as it excludes interest payments on that debt. It is ideal for analysts and potential investors looking to compare companies within the same industry.

Was macht Acasti Pharma Inc?

acasti pharma, inc., a subsiduary of neptune technologies & bioressources, is a quebec-based biopharmaceutical dedicated in advancing a proprietary portfolio based on marine phospholipids. our products can be used in prescription, medical food and over-the-counter applications, either as a stand-alone, or, as a fixed-dose combination to exisitng productrs, for the prevention and treatment of cardiometabolic disorders.